For two decades, vitamin B6 sat in the safest tier of the supplement aisle: cheap, familiar, and rarely questioned. That assumption is now under direct regulatory pressure in two of the world’s most influential natural health markets, and the read for the industry is bigger than a single ingredient.
In Australia, the Therapeutic Goods Administration has finalized a decision to reclassify higher-dose vitamin B6. From 1 June 2027, oral products delivering more than 50 mg per day and up to 200 mg will become Pharmacist Only Medicines, while products above 200 mg per day remain prescription-only. Only doses of 50 mg or less stay on open shelves. The trigger was an accumulation of adverse-event reports: as of October 2025, the TGA’s database held 250 reports of peripheral neuropathy and related nerve conditions linked to B6-containing products, recorded since January 2023. More than 100 products are expected to be affected.
Canada has moved on a parallel track, though with a lighter instrument. In a Summary Safety Review published in March 2026, Health Canada concluded there is a “possible link” between vitamin B6-containing natural health products and peripheral neuropathy at daily doses of 10 mg or higher. The regulator is updating its ingredient monographs and now expects licence holders to add neuropathy warnings to every B6 product at or above that 10 mg threshold. The scale is significant: more than 4,000 vitamin B6-containing NHPs are authorized in Canada at recommended doses of 10 mg or more.
Two regulators, two different mechanisms, one shared conclusion: a vitamin most consumers think of as harmless can carry a genuine safety signal, and “common vitamin equals low risk” is no longer a defensible default.
The science the industry stopped questioning
Peripheral neuropathy from excess B6 is not new. The textbook position held that toxicity appeared only at very high intakes — roughly 250 mg per day and above, sustained over time. That framing kept the category comfortable, because most multivitamins, energy formulas and B-complex products sit well below that line.
What changed is the evidence base. Health Canada’s review cited published cases of neuropathy at daily doses as low as 10 mg, and noted that no clear risk factors yet explain why some users are affected and others are not. The European Food Safety Authority reached a similarly cautious place in 2023, slashing its tolerable upper intake level for adults from 25 mg to 12 mg per day. The Netherlands’ pharmacovigilance centre and Australia’s adverse-event data point the same direction. When four respected regulators independently lower their thresholds within a few years, that is no longer an outlier reading — it is a trend line.
The commercial problem is that B6 is not confined to standalone pyridoxine tablets. It is a routine inclusion in B-complex formulas, energy and “metabolism” products, stress and sleep blends, pre-workout and women’s health lines, and supplemented foods such as energy drinks. The ingredient is everywhere, which means the regulatory exposure is everywhere too.
What this means for retailers
The immediate task is portfolio visibility. Most retailers do not know, off the top of their heads, how many SKUs on their shelves contain 10 mg or more of B6 — let alone how many sit above 50 mg. In the Canadian market especially, that number is likely far larger than category managers expect, because B6 hides inside combination products rather than announcing itself on the front of the pack.
Retailers operating in or sourcing from Australia face the sharper edge. Pharmacist-only status removes a product from open self-selection and places it behind a professional gatekeeper. For independent health food stores without a pharmacist on staff, higher-dose B6 lines simply leave the assortment. For pharmacy-integrated wellness operators, the same change is an opportunity: it pulls a previously commoditized product into the consultation zone, where margin and trust are higher.
In Canada, the near-term action is label compliance and shelf messaging. Products at 10 mg and above will carry neuropathy warnings, and retailers should expect questions at the point of sale. The smart move is to get ahead of the conversation rather than be caught flat-footed by it. Staff who can explain the warning calmly — that the signal concerns sustained high intake, that symptoms are typically reversible on stopping, and that food-sourced B6 is not the issue — protect both the sale and the customer relationship. Staff who shrug erode confidence in the whole category.
There is also a basket implication. B6 warnings invite shoppers to scrutinize their total intake across multiple products they may be stacking — a multivitamin plus a B-complex plus an energy formula. That is a merchandising prompt, not just a risk. It is an opening to move customers toward better-formulated, transparently dosed products and to position knowledgeable retail staff as the trusted filter consumers increasingly want.
What this means for brands
For manufacturers and formulators, the strategic question is whether to reformulate ahead of regulation or defend existing doses. The momentum across jurisdictions suggests reformulation is the lower-risk path for mass-market lines. Brands that proactively bring B6 down to defensible levels — and say so on pack — can turn a compliance chore into a positioning advantage at a moment when consumers are primed to reward restraint.
The harder calculation is for therapeutic positioning. Some B6 use is genuinely clinical — pregnancy nausea formulas, for instance, rely on the ingredient, and regulators have treated prescription pathways differently from open-shelf supplements. Brands with a legitimate higher-dose rationale will increasingly need to live in the pharmacist or practitioner channel rather than the open aisle, which changes packaging, claims and route to market.
Labelling discipline is now table stakes. Combination products that bury B6 content in a long ingredient panel are exactly the formats regulators and journalists scrutinize. Brands that lead with clear per-serving disclosure and a plain-language safety note will weather the news cycle far better than those that appear to be hiding the dose.
The bigger read: the “safe vitamin” era is ending
The most important takeaway is not about B6 at all. It is that regulators are now willing to challenge long-standing safety assumptions about mainstream ingredients, on the strength of pharmacovigilance data rather than catastrophic events. That willingness does not stop at one vitamin. The same logic — accumulating adverse-event reports, lowered upper limits, harmonization pressure — is already circling other high-dose nutrients and botanicals.
For an industry that has long traded on the public perception that vitamins are inherently benign, this is a structural shift. The competitive advantage is moving toward operators who treat dose, transparency and pharmacovigilance as commercial assets rather than regulatory friction. The brands and retailers that win the next decade will be the ones who can say, credibly and proactively, that they understood the risk before the regulator forced the conversation.
Vitamin B6 is the test case. The retailers and brands paying attention now — auditing their shelves, briefing their staff, and reformulating or repositioning where the data points — are not just managing a compliance event. They are rehearsing for the next ingredient, and the one after that.
